DMAC
Price
$4.09
Change
-$0.11 (-2.62%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
175.39M
61 days until earnings call
HUMA
Price
$2.62
Change
-$0.01 (-0.38%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
406.41M
75 days until earnings call
Interact to see
Advertisement

DMAC vs HUMA

Header iconDMAC vs HUMA Comparison
Open Charts DMAC vs HUMABanner chart's image
DiaMedica Therapeutics
Price$4.09
Change-$0.11 (-2.62%)
Volume$643
Capitalization175.39M
Humacyte
Price$2.62
Change-$0.01 (-0.38%)
Volume$53.78K
Capitalization406.41M
DMAC vs HUMA Comparison Chart
Loading...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HUMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DMAC vs. HUMA commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and HUMA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (DMAC: $4.09 vs. HUMA: $2.62)
Brand notoriety: DMAC and HUMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 108% vs. HUMA: 97%
Market capitalization -- DMAC: $175.39M vs. HUMA: $406.41M
DMAC [@Biotechnology] is valued at $175.39M. HUMA’s [@Biotechnology] market capitalization is $406.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green whileHUMA’s FA Score has 0 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • HUMA’s FA Score: 0 green, 5 red.
According to our system of comparison, HUMA is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 6 TA indicator(s) are bullish while HUMA’s TA Score has 5 bullish TA indicator(s).

  • DMAC’s TA Score: 6 bullish, 2 bearish.
  • HUMA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than HUMA.

Price Growth

DMAC (@Biotechnology) experienced а -2.39% price change this week, while HUMA (@Biotechnology) price change was -5.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

DMAC is expected to report earnings on Aug 06, 2025.

HUMA is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HUMA($406M) has a higher market cap than DMAC($175M). DMAC YTD gains are higher at: -24.678 vs. HUMA (-47.921). DMAC has higher annual earnings (EBITDA): -24.07M vs. HUMA (-137.16M). DMAC has more cash in the bank: 50.2M vs. HUMA (20.6M). DMAC has less debt than HUMA: DMAC (365K) vs HUMA (17.3M). DMAC (0) and HUMA (0) have equivalent revenues.
DMACHUMADMAC / HUMA
Capitalization175M406M43%
EBITDA-24.07M-137.16M18%
Gain YTD-24.678-47.92151%
P/E RatioN/AN/A-
Revenue00-
Total Cash50.2M20.6M244%
Total Debt365K17.3M2%
FUNDAMENTALS RATINGS
DMAC: Fundamental Ratings
DMAC
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
96
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DMACHUMA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 15 days ago
82%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HUMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BPAVX31.19N/A
N/A
Boston Partners All Cap Value Inv
BGORX21.89N/A
N/A
BlackRock Advantage International R
UGMVX11.52N/A
N/A
Victory Global Managed Volatility
GMVAX15.56N/A
N/A
Goldman Sachs Small/Mid Cap Value A
PETGX14.70N/A
N/A
Gabelli Pet Parents'™ A

HUMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with RXRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUMA
1D Price
Change %
HUMA100%
+0.77%
RXRX - HUMA
37%
Loosely correlated
+11.85%
PRLD - HUMA
37%
Loosely correlated
+6.91%
AURA - HUMA
36%
Loosely correlated
-3.00%
ACRV - HUMA
34%
Loosely correlated
+6.03%
CGON - HUMA
33%
Loosely correlated
-0.78%
More